RNXT (RenovoRx Corp) שולי הרווח הגולמי

סמל תאגידי ולוגו של RenovoRx Corp (RNXT)

The estimated gross margin for RenovoRx, Inc. (RNXT), with GURU.Markets data illustrated on this chart, demonstrates volatility where the parameter value equals 84.00. This price action is driven by strict FDA oversight, the patent protection of RenovoCath, and high-tech system assembly within the US. Business stability is further bolstered by minimal environmental impact through polymer disposal and adherence to office recycling protocols.

RNXT - רווחיות גולמית RenovoRx Corp בטווח 04.07.2022 - 20.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת RenovoRx Inc (RNXT)

- מדדי הערכת שווי שוק של העסק:
ניתוח בסיסי של החברה:RenovoRx Corp (RNXT)
מוצרים מוגמרים של RenovoRx

The development of RenovoRx, Inc. (RNXT) in the field of targeted chemotherapy through clinical alliances requires strict control over the implementation costs of the RenovoCath system. Gross margin measures the profit share after deducting direct production costs, demonstrating the efficiency of the operating model and the company's ability to scale innovations. By analyzing the gross margin rate, an investor can promptly identify rising costs of goods sold or the risk of capital overstocking.